Status:
TERMINATED
Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes
Lead Sponsor:
University of Maryland, Baltimore
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
21+ years
Phase:
PHASE4
Brief Summary
Beta-blockers are medications used to treat cardiovascular disease (CVD) symptoms, including high blood pressure and chest pain. People with diabetes who receive beta-blockers may experience adverse h...
Detailed Description
People with diabetes who develop CVD have worse health outcomes than people without diabetes who develop CVD. Beta-blockers are medications used to treat high blood pressure, angina (i.e., chest pain)...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Pre-Diabetes
Exclusion
- Insulin therapy
- Treatment with any beta-blocker in the 30 days before study entry
- Asthma
- Chronic obstructive pulmonary disease (COPD)
- Greater than first degree heart block
- Heart rate less than 60 bpm
- Systolic blood pressure less than 90 mm Hg
- Raynaud's phenomenon
- Known history of angina, heart attack, heart failure, coronary revascularization, or automatic implantable cardioverter defibrillators
- Pregnant
- Creatinine clearance less than 35 ml/min
- Hematologic dysfunction (white blood cell \[WBC\] count less than 3000 or hematocrit less than 28%)
- Allergy to amide anesthetics
Key Trial Info
Start Date :
December 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00925119
Start Date
December 1 2009
End Date
May 1 2014
Last Update
September 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Maryland
Baltimore, Maryland, United States, 21201